Bengaluru: Biocon has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received tentative approval from the U.S Food and Drug Administration (U.S. FDA) for its abbreviated new drug application ( ANDA) for Carbidopa and Levodopa Extended-Release Capsules, in 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg strengths.

Carbidopa and Levodopa Extended-Release Capsules are indicated for the treatment of Parkinson’s disease , post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Parkinson disease is a brain condition that causes problems with movement, mental health, sleep, pain and other health issues. It gets worse over time. Common symptoms of the disease include

See Full Page